NCT05534620View on ClinicalTrials.gov

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
DRUG

Treosulfan

IV infusion

DRUG

Fludarabine

IV infusion

Trial Locations (4)

10021

WITHDRAWN

Memorial Sloan Kettering Cancer Center, New York

23298

RECRUITING

VCU Massey Cancer Center, Richmond

43210

RECRUITING

The Ohio State University, Columbus

60612

RECRUITING

University of Illinois, Chicago

All Listed Sponsors
collaborator

Synteract, Inc.

INDUSTRY

lead

medac GmbH

INDUSTRY